{"id":6860,"date":"2025-09-15T23:05:46","date_gmt":"2025-09-15T23:05:46","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/09\/15\/biotech-news-atyr-cdc-fda-hims-astrazeneca\/"},"modified":"2025-09-15T23:05:46","modified_gmt":"2025-09-15T23:05:46","slug":"biotech-news-atyr-cdc-fda-hims-astrazeneca","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/09\/15\/biotech-news-atyr-cdc-fda-hims-astrazeneca\/","title":{"rendered":"STAT+: U.S. pressures U.K. as pharma pauses investments there"},"content":{"rendered":"<p>    STAT+: U.S. pressures U.K. as pharma pauses investments there<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Morning. Today, we see moves to potentially dismantle FDA ad comms, see the U.S. pressuring the U.K. over its stringent drug-pricing policy, and more.\u00a0<\/p>\n<h2 class=\"wp-block-heading\" id=\"h-the-need-to-know-this-morning\">The need-to-know this morning<\/h2>\n<ul class=\"wp-block-list\">\n<li>\n<strong>Monte Rosa Therapeutics<\/strong> signed a <a href=\"https:\/\/ir.monterosatx.com\/news-releases\/news-release-details\/monte-rosa-therapeutics-announces-collaboration-novartis\" rel=\"noopener\">research collaboration<\/a> agreement with <strong>Novartis<\/strong> to develop new treatments for autoimmune diseases based on Monte Rosa\u2019s protein degrader technology.\u00a0<\/li>\n<li>\n<strong>ATyr Pharma<\/strong> said its experimental drug efzofitimod <a href=\"https:\/\/investors.atyrpharma.com\/news-releases\/news-release-details\/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study\" rel=\"noopener\">failed to reduce<\/a> the use of oral steroids compared to placebo in a Phase 3 study of pulmonary sarcoidosis, a type of inflammatory lung disease.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\" id=\"h-fda-retreats-from-expert-drug-panels\">FDA retreats from expert drug panels<\/h2>\n<p>FDA leaders under President Trump are moving to curtail the agency\u2019s decades-old practice of convening public advisory committees to review drug applications. This is sparking worry that drug approval decisions could be shielded from outside scrutiny.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/09\/15\/biotech-news-atyr-cdc-fda-hims-astrazeneca\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/09\/15\/biotech-news-atyr-cdc-fda-hims-astrazeneca\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: U.S. pressures U.K. as pharma pauses investments there Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Morning. Today, we see moves to potentially dismantle FDA ad comms, see the U.S. pressuring the U.K. over its stringent drug-pricing policy, and more.\u00a0 The [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-6860","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6860"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=6860"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6860\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=6860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=6860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=6860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}